ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Deals and Collaborations: Firms Get First Payment From Bristol-Myers for Taxol

March 5, 1999

ASCO Urges NCI To Spell Out Metrics of Success Beyond Cutting Groups to Arbitrary Number

June 17, 2011

NIH Cancer Nurse Turnover Down to 10%

July 24, 1987

In Brief: Kennedy’s Oversight Hearings Will Include Cancer Program, Important To Act Renewal

January 26, 1979

Bristol-Myers Adds UCLA, Fox Chase To Grants Program

April 12, 1985

Kessler Says FDA Working To Expedite Secondary Approvals

January 31, 1992